1. Homepage
  2. Equities
  3. Germany
  4. Xetra
  5. Evotec SE
  6. Summary
    EVT   DE0005664809

EVOTEC SE

(EVT)
  Report
Real-time Estimate Quote. Real-time Estimate Tradegate - 05/16 03:59:57 pm
24.325 EUR   +0.77%
09:44aEVOTEC : Receives a Buy rating from Berenberg
MD
05/13EVOTEC : Raised to Buy by Deutsche Bank
MD
05/13EVOTEC : Upgraded to Buy by Deutsche Bank
MD
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Xetra
05/10/2022 05/11/2022 05/12/2022 05/13/2022 05/16/2022 Date
24(c) 21.45(c) 21.41(c) 24.14(c) 24.24(c) Last
1 071 691 1 342 253 925 237 586 445 288 408 Volume
+13.64% -10.63% -0.19% +12.75% +0.41% Change
More quotes
Estimated financial data (e)
Sales 2022 682 M 709 M 709 M
Net income 2022 -1,87 M -1,95 M -1,95 M
Net cash position 2022 86,0 M 89,5 M 89,5 M
P/E ratio 2022 1 355x
Yield 2022 -
Sales 2023 792 M 823 M 823 M
Net income 2023 41,9 M 43,6 M 43,6 M
Net cash position 2023 168 M 175 M 175 M
P/E ratio 2023 116x
Yield 2023 -
Capitalization 4 283 M 4 456 M 4 456 M
EV / Sales 2022 6,16x
EV / Sales 2023 5,20x
Nbr of Employees 4 354
Free-Float 87,7%
More Financials
Company
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug... 
More about the company
Ratings of Evotec SE
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B+
More Ratings
All news about EVOTEC SE
09:44aEVOTEC : Receives a Buy rating from Berenberg
MD
05/13EVOTEC : Raised to Buy by Deutsche Bank
MD
05/13EVOTEC : Upgraded to Buy by Deutsche Bank
MD
05/12EVOTEC : Deutsche Bank gives a Neutral rating
MD
05/12EVOTEC : Warburg Research reaffirms its Buy rating
MD
05/11EVOTEC : Jefferies reaffirms its Buy rating
MD
05/11EVOTEC : Gets a Buy rating from RBC
MD
05/11TRANSCRIPT : Evotec SE, Q1 2022 Earnings Call, May 11, 2022
CI
05/11Evotec SE Confirms Revenue Guidance for 2022
CI
05/11Evotec SE Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
05/11EVOTEC : Warburg Research reaffirms its Buy rating
MD
05/11Evotec SE reports results for the first quarter 2022 and provides corporate update
EQ
05/10EVOTEC : RBC reiterates its Buy rating
MD
05/10Evotec and Bristol Myers Squibb Extend and Expand Strategic Partnership
CI
05/10Evotec Expands Partnership With Bristol Myers Squibb
MT
More news
News in other languages on EVOTEC SE
05/13AKTIEN FRANKFURT : Dax erstmals seit längerer Zeit vor Wochengewinn
05/13AKTIEN FRANKFURT : Dax steuert nach Rücksetzer auf klaren Wochengewinn zu
05/11MÄRKTE EUROPA/Sehr fest nach US-Verbraucherpreisen
05/11AKTIEN FRANKFURT SCHLUSS : Dax steigt - US-Inflation bremst nur kurz
05/11XETRA-SCHLUSS/DAX setzt Erholung fort - Bayer sehr schwach
More news
Analyst Recommendations on EVOTEC SE
More recommendations
Chart EVOTEC SE
Duration : Period :
Evotec SE Technical Analysis Chart | EVT | DE0005664809 | MarketScreener
Technical analysis trends EVOTEC SE
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 10
Last Close Price 24,24 €
Average target price 36,44 €
Spread / Average Target 50,3%
EPS Revisions
Managers and Directors
Werner Lanthaler Chief Executive Officer
Enno Spillner Chief Financial Officer
Iris Löw-Friedrich Chairman-Supervisory Board
Cord E. Dohrmann Chief Scientific Officer
Craig L. Johnstone Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
EVOTEC SE-42.96%4 440
MODERNA, INC.-45.70%54 855
LONZA GROUP AG-27.63%40 862
IQVIA HOLDINGS INC.-26.03%39 504
SEAGEN INC.-12.27%24 966
ICON PUBLIC LIMITED COMPANY-31.87%17 153